Novartis, a pharmaceutical company, has not publicly terminated business relationships based on views or beliefs. Novartis scored a 100 on the 2023 Corporate Equality Index (CEI) from the Human Rights Campaign (HRC), a political stakeholder group. By complying with Human Rights Campaign’s controversial demands, Novartis increases the risk of dividing employees, alienating customers and harming shareholders. The company covers transgender-related medical costs for its employees and their children. It also uses sex and gender ideology criteria in employee recruitment, vendor selection, marketing, and philanthropic support. Novartis uses its reputation, corporate funds, and political influence to support controversial sex and gender ideologies, organizations, and legislation. The company provides a benefits package for employees which covers travel/lodging costs for an abortion and transgender medical procedures for covered employees and dependents, including children. Novartis does not provide its employees with protections against viewpoint discrimination. The company funds multiple LGBTQ organizations and supports the Equality Act. Novartis also may discriminate against some religious organizations in its charitable giving. For these reasons, Novartis receives a High Risk rating.